AAstrom Biosciences - 500 Beiträge pro Seite

[goasi]

Hallo Leute kann jemand etwas über diesen Wert am NASDAQ meine Informationen darüber sind sehr spärlich bin in Frankfurt mal so aus dem Bauch raus eingestiegen und hab leider eine schlechte Erfahrung gemacht, das einzige was ich weiß das diese Firma mit BBiotech zusammenarbeitet aber sonst fast nix. Wers weiß News oder Meldungen darüber bzw. was sich mit dem Kurs tun könnte.
Danke für Antworten im voraus.
m.f.G Goasi

P.S.:Hab leider schon 40% miese damit ?!?!?!?!
Oh Shit

[donvox]

Hallo Goasi!

Folgendes vom ragingbull board!

Aastrom Biosciences Initiates New Product Program for the Treatment of
BoneRelated Diseases - Positive Pre-Clinical Results Drive New Program -
Tue Apr 04 08:00:00 EDT 2000




ANN ARBOR, Mich., Apr 4, 2000 /PRNewswire via COMTEX/ -- Aastrom Biosciences,
Inc. (Nasdaq: ASTM) today announced that the Company has initiated a program to
develop its cell production technology and AastromReplicell(TM) System in the
treatment of bone related diseases. This program is intended to result in a new
therapy kit for use with the AastromReplicell(TM) System, which will be designed
to produce therapeutic quantities of bone-forming cells to aid in the treatment
of bone degenerative diseases such as Osteoporosis.

The initiation of this new product development program is based on results from
Aastrom`s pre-clinical studies, which demonstrated ex vivo production of human
bone-forming cells and on the evaluation of a patient case study, resulting from
Aastrom`s compassionate use program.

"Our scientists have generated exciting research data which resulted in the
initiation of this new program," stated R. Douglas Armstrong, Ph.D., President
and CEO of Aastrom Biosciences, Inc. "Our current product programs in stem cell
and cord blood therapies for cancer and leukemia are currently being evaluated
in pivotal clinical trials and our entrance into the bone disease arena is an
important next step for the Company and for the AastromReplicell(TM) System
product line."

The newly planned product, which is designated the OC-I Therapy Kit, will be
designed to work in conjunction with the AastromReplicell(TM) System. Using this
system, the production of bone-forming cells will begin with a small sample of
cells, taken from a patient or donor. The OC-I Therapy Kit will be used to
expand this small sample into a large quantity of the therapeutic bone-forming
cells. These new cells will then be infused into the patient, where they should
migrate to the bone areas, with the targeted result being the formation of new
bone.

Ex-Vivo Production and Evaluation of Bone Marrow Cells Expanded With the
AastromReplicell(TM) System

Aastrom`s scientists used the Company`s patented procedures for growing human
cells for these studies, and evaluated two sets of samples. The first set
included approximately 60 samples taken from healthy donors and the second set
included approximately 20 samples taken from breast cancer patients. Once
collected, both sets of tissues were evaluated to determine the number of
mesenchymal, or stromal progenitor cells (early stage cells responsible for bone
formation). A common measure of mesenchymal progenitor cells is an assay for
quantifying colony forming unit fibroblasts (CFU-F). The cell samples were then
expanded using the AastromReplicell(TM) System process and re-evaluated for
CFU-F. Results showed a median increase in CFU-F of approximately 60-fold in the
healthy donor samples and approximately 40-fold in the breast cancer samples.

Use of Bone-Forming Cells in Patients

The use of human bone forming cells as a medical treatment procedure is a new
therapeutic area. A recent study (Horowitz et al, Nature Medicine, Volume 5,
page 309, 1999) demonstrated that bone marrow-derived cells infused into
patients with osteogenic imperfecta (OI), matured into bone forming cells
(osteoblasts) and lessened the bone abnormalities associated with OI. Other
studies have shown that bone marrow cells can augment repair of vertebral
fractures.

Adding to this growing body of data is a patient case study involving a
pediatric patient with Hypophosphotasia. Infantile Hypophosphotasia is an
inherited disorder characterized by severe skeletal abnormalities and
hypercalcemia, which causes poor bone mineralization, increased bone fractures
and pulmonary complications. The disease is associated with a 50% mortality rate
and there is currently no known cure. In order to improve bone formation, the
patient received a donor-derived bone marrow transplant using cells produced in
the AastromReplicellTM System. The results seen in this patient provide further
evidence of the potential ability of these cells to lead to new bone formation.

The AastromReplicell(TM) System consists of an instrumentation platform designed
to operate a family of patient-specific cell therapy kits to produce cells for a
broad range of therapeutic applications. Each therapy kit is a single-use
consumable product that is tailored to the specific cell type desired for
therapeutic use. Aastrom has developed two such kits; the SC-I Therapy Kit for
the production of bone marrow-derived stem cells and the CB-I Therapy Kit for
the production of cord blood cells. Aastrom has initiated a phase III-pivotal
clinical trial evaluating the SC-I Therapy Kit in breast cancer patients and
plans to initiate a Phase III-pivotal trial of the CB-I Therapy Kit.

In addition to currently used stem cell therapies, many emerging cell therapies
are being developed at academic institutions and other companies. The
AastromReplicellTM System is designed to standardize these laboratory procedures
so that they may be incorporated into general medical practice. Once established
for use in stem cell therapy, Aastrom plans to leverage the cell manufacturing
capabilities of the AastromReplicell(TM) System across multiple cell therapy
opportunities by providing a commercialization outlet for these therapies as new
therapy kits, such as the OC-I Therapy Kit, for the AastromReplicell(TM) System
product pipeline.

Aastrom Biosciences, Inc. is pioneering the development of proprietary clinical
systems including the AastromReplicell(TM) System. Aastrom has received patents
covering methods and devices for the ex vivo production of human stem and other
types of cells, as well as for the genetic modification of these cells. The
AastromReplicell(TM) System is under development and is not available for sale
at this time in the U.S. except for research and investigational purposes.

This document contains forward-looking statements, including without limitation,
statements concerning clinical trial results, potential product applications of
the Company`s technology, product development programs, and potential advantages
of the AastromReplicell(TM) System, which involve certain risks and
uncertainties. The forward-looking statements are also identified through use of
the words "anticipates," "believes," "expects," "plans," and other words of
similar meaning. Actual results may differ significantly from the expectations
contained in the forward-looking statements. Among the factors that may result
in differences are the uncertainties inherent in clinical trial and development
activities, unforeseen potential problems in developing new therapy kits,
regulatory approval requirements, the availability of resources and potential
emergence or development of competing therapies. These and other significant
factors are discussed in greater detail in Aastrom`s Annual Report on Form-10K
and other filings with the Securities and Exchange Commission.

SOURCE Aastrom Biosciences, Inc.


(C) 2000 PR Newswire. All rights reserved.

http://www.prnewswire.com

http://www.ragingbull.com/news/news.cgi?articleid=CMTXAp2777


Klingt an sich sehr vielversprechend. ASTM konnte sich der Korrektur der letzten Wochen natürlich auch nicht entziehen.
Bin der festen Überzeugung, daß sich der Kurs bei der nächsten Veröffentlichung eines Forschungsergebnisses dementsprechend verhält.

gruß

donvox